Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)

SHA:603707 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,448	1,024	1,210	1,389	658.55	493.55
Trading Asset Securities	1,252	1,055	681.99	1.3	259.8	845.79
Cash & Short-Term Investments	2,699	2,080	1,892	1,390	918.35	1,339
Cash Growth	38.13%	9.94%	36.12%	51.34%	-31.43%	210.56%
Accounts Receivable	1,037	920.04	771.68	974.11	897.75	788.11
Other Receivables	252.13	273.46	230.88	241.94	167.88	107.21
Receivables	1,289	1,194	1,003	1,216	1,066	895.31
Inventory	3,404	3,675	4,158	5,616	4,894	4,457
Prepaid Expenses	-	13.17	11.98	8.46	7.98	10.11
Other Current Assets	138.31	84.42	196.99	64.14	43.62	65.9
Total Current Assets	7,530	7,046	7,262	8,294	6,930	6,768
Property, Plant & Equipment	1,211	1,197	1,235	1,198	827.42	532.83
Long-Term Investments	82.65	83.26	72.48	61.6	26.39	3.26
Goodwill	128.02	129.51	127.61	125.48	114.87	117.56
Other Intangible Assets	330.33	337.53	174.1	118.96	123.85	105.37
Long-Term Deferred Tax Assets	165.59	203.25	348.4	101.47	34.54	21.65
Long-Term Deferred Charges	806.12	459.55	294.24	94.62	77.65	55.52
Other Long-Term Assets	53.13	53.7	10.38	16.31	82.34	116.08
Total Assets	10,307	9,510	9,524	10,010	8,217	7,720
Accounts Payable	687.9	495.66	537.74	505.12	458.87	502.22
Accrued Expenses	222.11	207.11	294.85	88.15	64.56	47.26
Short-Term Debt	1,508	1,236	1,567	1,957	1,571	2,132
Current Portion of Long-Term Debt	534.16	8.21	505.45	0.42	-	-
Current Income Taxes Payable	25.99	3.72	29.31	0.44	8.73	17.42
Current Unearned Revenue	9.51	59.03	35.93	38.22	25.07	29.08
Other Current Liabilities	74.97	54.67	116.18	115.44	138.56	77.65
Total Current Liabilities	3,063	2,064	3,086	2,705	2,266	2,806
Long-Term Debt	322.33	824.16	512.37	997.36	480.75	1,132
Long-Term Leases	60.06	10.28	13.23	15.94	-	-
Long-Term Unearned Revenue	79.98	84.63	76.57	84.99	65.51	38.15
Long-Term Deferred Tax Liabilities	31.15	38.28	37.33	39.99	1.42	-
Total Liabilities	3,556	3,022	3,726	3,843	2,814	3,976
Common Stock	1,616	1,616	1,617	1,617	1,244	934.16
Additional Paid-In Capital	587.29	587.29	601.02	603.59	987.96	157.77
Retained Earnings	4,472	4,204	3,540	3,915	3,123	2,485
Treasury Stock	-10.22	-	-27.75	-32.82	-47.3	-14.43
Comprehensive Income & Other	89.98	84.62	72.5	67.9	70.45	159.79
Total Common Equity	6,755	6,492	5,802	6,171	5,378	3,722
Minority Interest	-3.53	-3.51	-3.47	-3.47	24.84	22.12
Shareholders' Equity	6,751	6,488	5,798	6,167	5,403	3,745
Total Liabilities & Equity	10,307	9,510	9,524	10,010	8,217	7,720
Total Debt	2,425	2,079	2,598	2,971	2,051	3,264
Net Cash (Debt)	274.62	1.13	-706.06	-1,581	-1,133	-1,925
Net Cash Per Share	0.17	0.00	-0.45	-0.97	-0.72	-1.21
Filing Date Shares Outstanding	1,591	1,616	1,473	1,653	1,543	1,662
Total Common Shares Outstanding	1,591	1,616	1,473	1,653	1,543	1,662
Working Capital	4,468	4,981	4,175	5,589	4,663	3,962
Book Value Per Share	4.25	4.02	3.94	3.73	3.49	2.24
Tangible Book Value	6,296	6,025	5,500	5,926	5,139	3,500
Tangible Book Value Per Share	3.96	3.73	3.73	3.58	3.33	2.11
Buildings	-	472.9	481.48	448.47	268.49	164.68
Machinery	-	1,323	1,279	981.72	751.74	606.4
Construction In Progress	-	137.44	79.74	250.62	215.26	99.68

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.